Nasus Pharma (NSRX) Equity Average (2025)
Nasus Pharma (NSRX) reported Equity Average of -$773000.0 for Q4 2025, up 79.46% quarter-over-quarter from -$3.8 million in Q2 2025.
Nasus Pharma (NSRX) Equity Average (2025) Analysis & Trends
Nasus Pharma has reported Equity Average for 1 years, with the latest figure at -$773000.0 in Q4 2025.
- For the quarter ending Q4 2025, Equity Average changed N/A year-over-year to -$773000.0; the trailing twelve-month figure through Dec 2025 stood at -$773000.0 (changed N/A YoY), and the FY2025 full-year result was -$222000.0, up 93.67% from the prior year.
- Equity Average for Q4 2025 stood at -$773000.0, up from -$3.8 million in the prior quarter.
- The five-year high for Equity Average was -$773000.0 in Q4 2025, with the low at -$3.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | -773,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -773,000.00 |
| Jun 30, 2025 | -3.76 Mn |